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A small-molecule mimetic of Smac/Diablo that specifically counters the apoptosis-inhibiting activity
of IAP proteins has been shown to enhance apoptosis induced by cell surface death receptors aswell
as chemotherapeutic drugs. Survey of a panel of 50 human non-small-cell lung cancer cell lines has
revealed, surprisingly, that roughly one-quarter of these lines are sensitive to the treatment of Smac
mimetic alone, suggesting that an apoptotic signal has been turned on in these cells and is held in
check by IAP proteins. This signal has now been identified as the autocrine-secreted cytokine tumor
necrosis factor alpha (TNFa). In response to autocrine TNFa signaling, the Smac mimetic promotes
formation of a RIPK1-dependent caspase-8-activating complex, leading to apoptosis.INTRODUCTION
Cancer is second only to heart disease as the leading
cause of death in industrialized countries. Although mor-
tality rates have declined in recent years due to earlier
detection and more options in treatment, the outlook for
certain cancers remains bleak (Workman and Kaye,
2002). For example, lung cancers, despite treatment ad-
vances, have a general long-term survival rate of only
15%. Conventional cancer chemotherapeutics such as
paclitaxel, cisplatin, topotecan, or etoposide have a small
therapeutic index between cancer and normal cells. Com-
plicating matters further is the almost inevitable onset of
resistance and subsequent relapse.
In recent years, the focus has shifted to less-toxic ther-
apeutics that target specific signaling pathways drivingCainappropriate cell growth and proliferation. Examples
include imatinib and erlotinib, rationally-designed tyrosine
kinase inhibitors that block the ATPbinding site of the con-
stitutively active BCR-ABL tyrosine kinase translocation
mutation found in chronic myeloid leukemia (CML)(Druker,
2002) and the tyrosine kinase domain mutant EGFR found
in non-small-cell lung cancers. Monoclonal antibodies
such asHerceptin, which targets theHER2/neu (erbB2) re-
ceptor that is often amplified in breast cancer, have also
been developed (Izumi et al., 2002; Slamon et al., 2001).
In addition to aberrant growth signals, many cancers
also have dysfunction in the ability to undergo apoptosis
(Danial and Korsmeyer, 2004; Hanahan and Weinberg,
2000). Overexpression of antiapoptotic genes have been
correlated with tumorigenesis and resistance to chemo-
therapy. A classic example is seen in non-Hodgkin’sSIGNIFICANCE
The use of small-molecule mimetics of Smac offers significant potential in the treatment of many cancers, given
that the Smac protein functions to uninhibit apoptosis by relieving IAP inhibition of caspases. The intended appli-
cation of such a compound was to complement the effectiveness of other chemotherapeutic agents; hence, the
apparent ability of a Smac mimetic, in one-quarter of cell lines tested, to induce cell death as a single agent
was quite remarkable. Not only is single-agent Smac mimetic treatment highly effective at inducing cell death in
these cell lines as well as in xenografts, but it offers the possibility of highly specific and relatively nontoxic future
therapeutic treatments by exploiting certain cancer cells’ own production of TNFa.ncer Cell 12, 445–456, November 2007 ª2007 Elsevier Inc. 445
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Autocrine TNFa Renders Smac Mimetic Sensitivitylymphoma, where constitutive Bcl-2 overexpression
blocks apoptosis in the presence of proapoptotic stimuli
(Kirkin et al., 2004; Miyashita and Reed, 1993). Addition-
ally, overexpression of various members of the inhibitor
of apoptosis (IAP) family of proteins has also been found
in cancers able to evade apoptosis (Gordon et al., 2002;
Nachmias et al., 2004; Sui et al., 2002). An alternative ap-
proach to the treatment of cancer, therefore, would be to
reestablish the cell death program and set conditions such
that cells can undergo apoptosis given an appropriate
stimulus (Fesik, 2005). The potential of such tactics can
be seen by the emergence of small-molecule inhibitors
targeting various components of the regulatory system
of apoptosis. Olterdorf and coworkers recently identified
a potent small-molecule inhibitor targeting Bcl-2, Bcl-XL,
and Bcl-w that was able to synergize with other chemo-
therapeutics as well as having single-agent actions
against lymphoma and small-cell lung cancer with signifi-
cant cure rates in animal models (Oltersdorf et al., 2005).
In addition, small-molecule inhibitors of second mito-
chondria-derived activator of apoptosis (Smac) have re-
cently been developed that promote apoptosis in synergy
with other proapoptotic stimuli (Bockbrader et al., 2005;
Chauhan et al., 2007; Glover et al., 2003; Li et al., 2004;
Mizukawa et al., 2006; Sun et al., 2005, 2006; Wilkinson
et al., 2004; Wu et al., 2003; Zobel et al., 2006). Smac is
an ideal candidate for small-molecule mimetic design
and therapeutic application because of its unique function
in regulating apoptosis. Under normal conditions, Smac is
sequestered in the mitochondria and is released into the
cytosol only upon induction of apoptosis or mitochondrial
dysfunction (Chai et al., 2000; Du et al., 2000). Once in the
cytosol, Smac is able to bind its targets, which consist
of a family of related proteins known as the inhibitors of
apoptosis (IAPs) (Liu et al., 2000; Srinivasula et al., 2001;
Wu et al., 2000). IAPs function to prevent unregulated ac-
tivation of the apoptotic cell death program by binding to
and inhibiting multiple proteins necessary for apoptosis to
occur. For example, XIAP (X chromosome-encoded IAP)
binds to activated caspases-3, -7, and -9 and inhibits their
activities (Crook et al., 1993; Deveraux et al., 1997; Roy
et al., 1997). A key feature of regulated apoptosis is the
release of Smac from mitochondria and the subsequent
release of caspases from inhibition. A mimetic of Smac is
able to relieve caspases from inhibition without need for
mitochondrial disruption to promote apoptosis in cancer
cells given an additional proapoptotic stimulus.
Previously, our laboratory demonstrated the feasibility
of such an approach by preparing a small-molecule
mimetic of Smac and showed that it permeates cells read-
ily and acts in a similar fashion as natural Smac in the cell
while bypassing mitochondrial regulation (Li et al., 2004).
The small-molecule mimetic is a synthetic, two-headed
structure designed to resemble the N-terminal amino
acid residues (AVPI) of Smac protein that interact with
BIR domains of XIAP (Wu et al., 2000). The compound
was shown to bind specifically to at least three members
of the IAP family: XIAP, cellular IAP 1 (cIAP1), and cIAP2.
It was able to promote apoptosis synergistically with proa-446 Cancer Cell 12, 445–456, November 2007 ª2007 Elsevier Ipoptotic stimuli (TRAIL or TNFa) that on their own have no
effect on cell death in the cancer cell lines examined (Li
et al., 2004).
In addition to inhibiting caspase activation, an ancillary
function of both cIAP1 and cIAP2 is that both proteins
are implicated in nuclear factor kappa B (NFkB) activation
(Chen et al., 2002; Shu et al., 1996) and suppression of
caspase-8 activation during TNFa signaling (Deveraux
et al., 1998;Wang et al., 1998). TNFa is a pleiotropic ligand
of tumor necrosis factor receptor 1 and 2 (TNFR1 and
TNFR2) that can signal both cell survival and cell death
(Aggarwal, 2003; Bhardwaj and Aggarwal, 2003; Wajant,
2003). The prosurvival and prodeath signaling aspects of
TNFa are mediated through two separate protein com-
plexes (Micheau and Tschopp, 2003). The prosurvival
complex, in addition to TNFa bound to TNFR1, also
contains the adaptor protein TNFR1-associated death do-
main protein (TRADD), TNF-receptor-associated protein 2
(TRAF2), receptor-interacting protein kinase 1 (RIPK1),
and cIAP1 and cIAP2. This complex recruits and activates
I kappa kinases (IKK), leading to the activation of NFkB
(Devin et al., 2000; Shu et al., 1996). A prodeath complex
is also formed, but as long as there is a prosurvival signal
being generated, it is unable to induce cell death. The
death-inducing complex assembles following internaliza-
tion of the TNFR1 receptor and consists of TRADD and
RIPK1, which then recruit Fas-associated protein with
death domain (FADD) and caspase-8 to generate the
death inducing signaling complex (DISC) (Micheau and
Tschopp, 2003).
Here, we report the finding that various human cancer
cell lines undergo apoptosis upon Smac mimetic treat-
ment without the need for exogenous proapoptotic stimuli
or cotreatment with chemotherapeutic agents. We have
elucidated the molecular mechanism underlying this sin-
gle-agent sensitivity. Our work reveals a functionality of
the Smac mimetic relating specifically to TNFa signaling
that is distinct from simple interference with caspase inhi-
bition. The Smac mimetic is able to exploit certain cancer
cells that secrete TNFa and usurp this prosurvival signal
to promote cell death via formation of a RIPK1-dependent,
death-inducing complex.
RESULTS
A Smac Mimetic Induces Cell Death in Human
Non-Small-Cell Lung Cancer Cell Lines
and Specifically Targets IAPs
Initial testing of various cell lines to the synergistic effects
of Smac mimetic treatment with conventional chemother-
apeutics revealed a subset of cells that responded to the
Smac mimetic alone (data not shown). A larger panel of
non-small-cell lung cancer (NSCL) cell lines was therefore
screened for responsiveness to the Smac mimetic
(Figure 1A). Of the 50 cell lines examined, 14% responded
to low nanomolar concentrations, and an additional 8%
had IC50s in the low micromolar range. The majority of
cells (78%) were unresponsive to Smac mimeticnc.
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Autocrine TNFa Renders Smac Mimetic SensitivityFigure 1. Response of a Panel of Lung Cancer Cell Lines to Smac Mimetic In Vitro and In Vivo
(A) A panel of 50 non-small-carcinoma-cell lung cancer cell lines was tested for responsiveness to a Smac-mimetic treatment alone. IC50s were de-
termined for each cell line based on cell survival as measured by ATP levels in live cells using Cell Titer-glo (Promega). IC50 determination was based
on concentrations of compound 3 that yielded half-maximal luminescence relative to untreated cells.
(B) Treatment of selected group of cell lines to 100 nM of compound 3 and to compound 4 (negative control compound with similar structure by dif-
fering in function group configuration as described in Li et al., 2004). Smac-mimetic-sensitive cell lines (HCC44 and HCC461) and Smac-mimetic-
resistant cell lines (HCC827 and H2009) were chosen. Each graphical representation for IC50s and cell survival indicates the mean ± SD of at least
three independent testing conditions.
(C) In vitro pull-down utilizing a biotinylated form of compound 3. The biotinylated compound was able to pull down protein bands at around 50 kDa
and at around 70 kDa not seen in control lanes (avidin beads only), which were cut out of the gel and analyzed by mass spectroscopy. Proteins iden-
tified are indicated.
(D) In vivo responseofmouse xenografts of HCC461 cells to compound 3.Harlan athymic nudemicewere injected subcutaneouslywithHCC461 cells in
a matrigel randomly separated into treatment groups (n = 5) and given six intravenous injections of compound 3 or saline every other day. Tumors were
measured twiceperweekuntil theendof theexperiment. In thecompound3 treatmentgroup,2/5 (40%) remainedtumor-freeat theendof theexperiment.
(E) In vivo response of mouse xenografts of a Smac-mimetic-resistant HCC15 cells to compound 3. Conditions were identical to those for HCC461
xenografts. For tumor size measurements, graphical representations indicate the mean ± SEM of five individual samples per condition.concentrations up to 100 uM. Closer inspection of two
sensitive lung cancer cell lines (HCC44 and HCC461)
showed that these cells respond robustly to 100 nM treat-
ment of Smac mimetic, with approximately 80% of the
cells killed by the Smac mimetic after 24 hr of treatment
(Figure 1B). To ensure that these effects were specific,
a compound with its critical alanine group acetylated,
and therefore inactivated as a Smac mimetic, was also
used (Li et al., 2004). Neither HCC461 nor HCC44 cell lines
were sensitive to the treatment of this inactive compound.
Two other lung cancer cell lines (H2009 and HCC827)
were resistant to 100 nM Smac mimetic treatment
(Figure 1B).CancTo ensure that the Smac mimetic was specifically
targeting IAPs in these cells, a biotinylated form of the
Smac mimetic was synthesized and used for in vitro
pull-down to determine what precisely the Smac mimetic
was interacting with in these cells. Whole cell lysates were
incubated with the biotinylated Smac mimetic and inter-
acting proteins were pulled down with avidin-coated
beads and analyzed by SDS-PAGE followed by silver
staining (Figure 1C) andmass spectrometry. As compared
to the affinity matrix alone, the biotinylated Smac mimetic
specifically pulled down two protein bands visualized by
silver staining. Mass spectrometric analysis of these
bands revealed that the band around the 70 kDa markerer Cell 12, 445–456, November 2007 ª2007 Elsevier Inc. 447
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consisted of XIAP, TRAF2, and TRAF1. TRAF1 and TRAF2
were most likely copurified with cIAP1 and cIAP2, since
they have been shown previously to interact and formmul-
tisubunit complexes involved in NFkB activation (Rothe
et al., 1995). It is evident from the above result that the
Smac mimetic is highly specific in interacting with IAP
proteins. Interestingly, although there was no significant
difference in XIAP/TRAF1/TRAF2 pulled down from sensi-
tive (HCC44 and HCC461) or nonsensitive (HCC827 and
H2009) cell extracts, there seemed to be more cIAPs
from the sensitive cells pulled down by the biotinylated
Smac mimetic.
Smac Mimetic Alone Induces Tumor Regression
in HCC461 Xenograft Model
Observing the robustness of HCC461 cell death induced
by the Smac mimetic alone in cell culture, we decided to
examine whether such a property remained unchanged
in a xenograft mouse tumor model. HCC461 cells were
grown in matrigel and injected subcutaneously into athy-
mic nude mice. Tumors were allowed to grow for 7 days
(average tumor size: 200-300 mm3). Tumor-bearing mice
were thereafter given six separate intravenous injections
of either Smac mimetic or saline over the following
11 days (D7, 9, 11, 13, 15, 17). As shown in Figure 1D,
mice treated with saline did not survive past day 30 (aver-
age tumor size: 2200 mm3), while mice treated with the
Smac mimetic showed marked and sustained tumor re-
gression (average tumor size: < 50 mm3). At day 40, tu-
mors began to gradually reappear, but these were still sig-
nificantly smaller at day 50 (average tumor size: 500 mm3)
than control tumors at day 30. Of the mice treated with the
Smac mimetic, 2 out of 5 (40%) were tumor free at the end
of the experiment. This result is quite different than that
obtained from a breast cancer xenograft mouse model
treated with the same Smac mimetic compound at the
same doses (5 mg/kg) and dosing schedule. In the breast
cancer model, Smac alone had little effect, and the mice
needed to be dosed together with Trail to achieve similar
therapeutic effect (data not shown). To ensure that the
xenograft response was specific to cell lines that showed
sensitivity in cell culture, an additional resistant NSCL
cancer cell line, HCC15, was also tested for responsive-
ness to the Smac mimetic alone. As shown in Figure 1E,
this cell line that was resistant to Smac mimetic treatment
in cell culture remained so in vivo under identical condi-
tions as were used to test HCC461.
Smac-Mimetic-Induced Apoptosis
HCC461 was examined in greater detail to determine how
exactly the Smacmimetic caused cell death in cell culture.
Time-course measurements of caspase activation re-
vealed that apoptosis was the mechanism of cell death
and that within 6 hr of Smacmimetic treatment, the execu-
tioner caspase-3 was activated (Figure 2A). Prior to that,
the initiator caspase-8 (Figure 2B) and caspase-9 (data
not shown) were activated at approximately 4 hr. Further-
more, inhibition of caspase activation by a pancaspase448 Cancer Cell 12, 445–456, November 2007 ª2007 Elsevier Iinhibitor, z vad fmk (z vad), prevented cleavage of cas-
pases-3, -8 and -9 following 6 hr of Smac mimetic treat-
ment (Figures 2A and 2B and data not shown, respec-
tively). Caspase inhibition was also correlated with
response to Smac mimetic, where a 1 hr z vad pretreat-
ment was able to rescue cells from cell death following
24 hr of Smac mimetic treatment (Figure 2C). The effects
of z vad were also tested for long-term survival in the pres-
ence of Smac mimetic. Cells were treated with Smac
mimetic, z vad, or both for 5 days to ensure that rescue
by z vad was permanent and that rescue was not a tran-
sient artifact of z vad exposure. As shown in Figure 2D,
cells treated with Smacmimetic plus z vad were still viable
after 5 days, whereas cells treated with the Smac mimetic
alone were killed.
Smac-Mimetic-Induced Apoptosis Occurs through
Engagement of TNFR1 by TNFa
Because both caspase-8 and caspase-9 are activated
in the same time frame, a candidate short-interfering
RNA (siRNA) screen was used in HCC461 to determine
which caspase was the initiator of apoptosis and ulti-
mately what signaling pathways mediates Smac-mimetic-
induced apoptosis. Experiments using siRNAs to knock-
down caspase-8 or caspase-9 revealed that transient
knockdown of caspase-8 rescued cells from cell death,
while knockdown of caspase-9 had no effect on cell viabil-
ity (Figure 3A). Given that caspase-8 activation is most
likely caused by certain members of the TNF super-family
of receptors, further screening of those receptors was
conducted. The canonical members of the death receptor
family are TNFR1, TRAIL receptor 1 (TRAIL-R1/DR4),
TRAIL receptor 2 (TRAIL-R2/DR5), and Fas/CD95 (Aggar-
wal, 2003). siRNA knockdown of TNFR1 rescued cells
from Smac-mimetic-mediated cell death, whereas knock-
down of the other receptors had little or no effect (Fig-
ure 3B and data not shown). Further knockdown of the
ligands of TNFa, TRAIL, and FasL confirmed that TNFR1
is a critical component, since knockdown of TNFa was
also able to rescue cells from apoptosis (Figure 3C and
data not shown). Knockdown efficiencies of the siRNAs
used were determined by western blotting utilizing three
individual siRNA oligos (Figure 3D).
Since TNFR1-TNFa signaling appears to be a require-
ment for the Smac-mimetic-induced apoptosis, we
reasoned that these cells might be secreting TNFa into
the culturemedium. Elisa analysis of the conditional media
from these cells revealed that sensitive cell lines (HCC44
and HCC461) were secreting TNFa into the culture
medium over time, whereas resistant cell lines (HCC827
and H2009) were not (Figure 4A). To validate that TNFa
secretion was critical for the Smac-mimetic-induced cell
death, HCC461 cells were pretreated with a neutralizing
TNFa antibody (1–2 mg/ml) (Oettinger et al., 1999) and
then treated with the Smac mimetic. As shown in
Figure 4B, the TNFa neutralizing antibody completely
rescued cells from apoptosis, whereas neutralizing anti-
bodies against TRAIL and FasL (1–2 mg/ml) had no rescu-
ing effect.nc.
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Analysis of caspase activation in HCC461 cell lysates following a time course of 100 nM compound 3 treatments. For caspase inhibition, 10 mM z vad
fmk (Sigma) was added 1 hr prior to compound 3.
(A) Western blot analysis of caspase-3 activation.
(B) Western blot analysis of caspase-8 activation.
(C) Rescue of Smac mimetic cell death by 10 mM z vad.
(D) Long-term survival of cells treatedwith z vad plus compound 3. Cells were treated as indicated for 5 days to ensure that rescue from cell death was
not a transient artifact of z vad treatment. Cell viability was determined using methylene blue staining. Each graphical representation indicates the
mean ± SD of at least three independent testing conditions.Smac-Mimetic-Mediated Cell Death Is Dependent
on RIPK1
Although the Smac mimetic alone requires endogenous
TNFa signaling to induce cell death, there is a seeming
incongruity between the fact that the Smac mimetic inter-
feres with IAP-caspase interactions and that under normal
conditions, TNFa is a prosurvival signal that upregulates
antiapoptotic genes including cIAP1 and cIAP2 (Wang
et al., 1998). Indeed, given cIAP1 and cIAP20s purported
roles in NFkB signaling, there is no apparent disruption
of basal NFkB activation, which is a key mediator of sur-
vival signaling, upon Smac mimetic treatment in these
cells (Li et al., 2004). However, the Smac mimetic is still
able to initiate apoptosis even under conditions of consti-
tutively active TNFa signaling by autocrine secretion.
Therefore, to determine how the Smac mimetic is able to
initiate apoptosis under such conditions, experiments
using siRNAs to target components of the TNFa signaling
pathwaywere carried out to determine which components
were necessary for cell death to occur.
Targeting of components known to be part of the TNFa
signaling pathway revealed that caspase-8 activation and
subsequent cell death were RIPK1 dependent. siRNACancknockdown of RIPK1 completely rescued cells from apo-
ptosis, while knockdown of the adaptor protein TRADD
seemed to enhance cell death, and knockdown of FADD
had only a partial rescue effect (Figure 5A). The effect of
RIPK1 knockdown was verified by four different siRNA
oligos that target different segments of the mRNA.
RIPK1 dependence in Smac-mimetic-mediated cell death
was unexpected, given the traditional view that RIPK1 is
involved more in NFkB survival signaling than in signaling
apoptosis. This finding is consistent with a recent report
showing that shRNA knockdown of RIPK1 prevented
TNFa-induced apoptosis in human tumor cells (Jin and
El-Deiry, 2006). However, the precise function of RIPK1
in survival and in cell death is not yet clear. Overexpres-
sion of RIPK1 was shown to be able to sensitize 293 cells
to apoptosis by TNFa treatment (Hsu et al., 1996),
whereas RIPK1-deficient Jurkat T cells do not activate
NFkB when treated with TNFa and are sensitized to
TNFa-induced apoptosis (Kelliher et al., 1998; Ting et al.,
1996). Knockdown efficiencies for RIPK1, FADD, and
TRADD were examined by western blot (Figure 5B).
Given the apparent role of RIPK1 in Smac-mimetic-me-
diated cell death, it might be possible the Smacmimetic iser Cell 12, 445–456, November 2007 ª2007 Elsevier Inc. 449
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Autocrine TNFa Renders Smac Mimetic SensitivityFigure 3. Sirna Candidate Screen Implicates TNFa Signaling as a Requirement for Smac-Mimetic-Mediated Apoptosis
Cells were assayed for the ability of particular transiently transfected individual siRNAs (Dharmacon) to produce a rescue phenotype in HCC461 cells
following 100 nM compound 3 treatments. Cell viability was determined by measuring total ATP levels. Each siRNA treatment and corresponding
compound treatment (n = 4, per transfection and compound 3 treatment) was normalized to the mock-transfected control to account for cytotoxicity.
(A) Caspase-8 and -9 siRNA transfection.
(B) TNFR1 siRNA transfection.
(C) TNFa siRNA transfection.
(D) Efficiency of total protein level knockdown per siRNA was determined by western blot. Caspase-8-positive controls in (B) and (3) utilized Dhar-
macon’s siGENOME SMARTpool predesigned pools of four oligos. Each graphical representation indicates the mean ± SD of at least three indepen-
dent testing conditions.somehow able to allow the formation of a RIPK1 contain-
ing signaling complex that activates caspase-8, hence
overriding the otherwise prosurvival signal of TNFa. Immu-
noprecipitation of caspase-8 following Smac mimetic
treatment revealed the formation of a RIPK1-FADD-cas-
pase-8 complex that did not contain TRADD or TRAF2
(Figure 5C). Formation of the complex was enhanced by
pretreatment with z vad, likely due to the fact that z vad
prevents full activation of caspase-8 and is able to trap
caspase-8 into the RIPK1-FADD-caspase-8 complex,
which would normally disassociate following full cas-
pase-8 activation. Similar coimmunoprecipitation experi-
ments of caspase-8 in cells that are unable to respond
to the Smac mimetic (HCC827) showed that they do not
readily form a RIPK1-FADD-caspase-8 complex when
the Smac mimetic and TNFa are added (data not shown),
indicating that formation of this complex is a requirement
for cell death to occur.450 Cancer Cell 12, 445–456, November 2007 ª2007 Elsevier ISingle-Agent Sensitivity to the Smac Mimetic
in Other Cell Lines Is Similarly Due
to TNFa Signaling
In addition to HCC461 cells as described above, other cell
lines including another lung cancer line (HCC44), a breast
cancer line MDA-MB-231, and a melanoma SK MEl-5 cell
line, undergo Smac mimetic-induced apoptosis in a TNFa
and RIPK1 dependendent fashion. siRNA knockdown of
caspase-8, TNFR1, TNFa, and RIPK1 as well as addition
of neutralizing TNFa antibody to the culture media res-
cued these cell lines from cell death (Figures 6A–6C). Ad-
ditionally, in the case of cell lines that are resistant to Smac
mimetic alone but do respond to costimulation by TNFa
(H2009 and T98G), siRNA knockdown of caspase-8,
TNFR1, and RIPK1 revealed that in cases where exoge-
nous TNFa is added, the mechanism of response is the
same as that for cells able to secrete TNFa (Figure 6D
and data not shown).nc.
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Required for Smac-Mimetic-Mediated
Apoptosis
(A) Smac-mimetic-sensitive cell lines (HCC44
and HCC461) and Smac-mimetic-resistant
cell lines (HCC827 and H2009) were tested
for the presence of TNFa in conditioned cell
culture media for each cell line. Samples
were removed at the indicated time points
and used for quantitative sandwich enzyme
immunoassay analysis (R&D Systems) to de-
termine the concentration of TNFa present,
as described in the Experimental Procedures
section. Sensitive cells were secreting low
levels of TNFa in the cell culture medium, while
there was no detectable TNFa levels present in
resistant cell lines.
(B) Pretreatment (1 hr) of neutralizing anti-
bodies (1–2 ug/mL) against TNFa (R&D Sys-
tems), TRAIL (Biolegend), and FasL/CD95
(Biolegend) prior to 100 nM compound 3 treat-
ments. Cell viability was determines as previ-
ously described. Each graphical representa-
tion indicates the mean ± SD of at least three
independent testing conditions.DISCUSSION
The perennial challenge in cancer drug discovery is spec-
ificity; namely, how to eradicate cancer cells without
harming normal tissues. Most currently used therapeutics
indiscriminately target fast growing cells regardless of
origin. Among the hallmark characteristics that cancer
cells display are the ability to evade apoptotic signals
such as oncogene transformation, resulting in unregulated
growth and proliferation, hypoxia, lack of proper growth
factor stimulation or inhibition, and genomic instability,
which will normally induce apoptosis. As knowledge of
the selectivemolecular mechanisms bywhich cancer cells
are able to grow, proliferate, and evade apoptosis is being
gained, therapeutically viable targets present themselves.
The now classic example is Gleevec. Selective growth
advantages that the constitutively activated BCR-ABL
kinase translocationmutation provides CML also presents
an ideal single-agent target that if successfully blocked,
would restore the proper balance of signaling to the cell.
Similarly, many cancers have also been shown to upregu-
late antiapoptotic genes, which when overexpressed con-
fer resistance to apoptosis, making such targets ideal
candidates for therapeutic intervention. Here, we identify
autocrine TNFa production as another potential means
by which cancer cells gain selective growth advantage
and resistance to apoptosis and a means by which a sin-
gle-agent Smac mimetic can exploit that signal to restore
sensitivity to apoptosis.CanThe above results suggest that targeting of the IAPs via
Smac mimetic is a promising strategy for the treatment of
cancer. Specifically, we show that targeting the IAPs
through the use of a small-molecule mimetic of Smac
had the unintended but fortuitous effect of also altering
the functional state of the TNFa receptor from one that
signals through the NFkB survival pathway to one that
also promotes the formation of a RIPK1-dependent,
death-inducing complex that is able to override the pro-
survival signal and initiate apoptosis. Furthermore, the
Smac mimetic is able to do this by exploiting the tumor
cell’s own pool of TNFa, in the form of autocrine secretion.
It seems likely that cells that produce autocrine TNFa
might rely on such a signal for survival, particularly to acti-
vate prosurvival and antiapoptotic genes regulated by
NFkB, and that such dependence might be the difference
between Smac-mimetic sensitivity and Smac-mimetic
resistance. Namely, because IAPs play potentially signifi-
cant and unique roles in TNF-mediated activation of NFkB,
that such cells would be particularly sensitive to the Smac
mimetic. Other cell lines may rely on other cytokines and
growth factors for such signaling and be resistant because
IAPs do not play a significant role in signaling in these
other systems. Given the identification of cancer cells that
secrete TNFa and that rely on TNFa for survival signaling, it
is possible that cancers fitting such a profilewould be ideal
targets of single-agent, smac-mimetic therapy.
In addition, Smac-mimetic-alone treatment of human
tumor (HCC461) xenografted into mice reduced the sizecer Cell 12, 445–456, November 2007 ª2007 Elsevier Inc. 451
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Autocrine TNFa Renders Smac Mimetic SensitivityFigure 5. Smac-Mimetic-Mediated Apoptosis Is RIPK1 Dependent and Promotes the Formation of a RIPK1-FADD-Caspase 8
Complex in HCC461 Cells
(A) siRNAs targeting known components of the TNF signaling pathway (FADD, TRADD, and RIPK1). RIPK1 dependence was verified by the use of
single siRNA oligos targeting different regions of the mRNA. siRNA transfection and viability assays were done as previously described.
(B) Western blot analysis of protein levels following siRNA transfection, as described previously.
(C) RIPK1, FADD, caspase-8 complex coimmunoprecipitation using caspase-8 antibody (Santa Cruz, SC-6136). Cells were treated in the indicated
manner and coimmunoprecipitations were done as described in the Experimental Procedures. Z vad was added as a means of capturing caspase-8
in complex with RIPK1 and FADD by preventing full activation and subsequent dissociation of the complex from caspase-8. Each graphical repre-
sentation indicates the mean ± SD of at least three independent testing conditions.of tumors over an extended period of time. Tumors treated
with Smac mimetic showed immediate response by re-
ducing in size to nearly undetectable levels and staying
that way for an extended period of time. Only 30 days after
the final treatment did the tumors start to reemerge, and
within the treatment group, 40% remained tumor free at
the end of the experiment. This experiment suggests
that the single-agent sensitivity observed in cultured cells
maintained this property in animals. Unfortunately, al-
though the secreted TNFa was readily detectable with
a simple Elisa method in the culture media when these
single-agent-sensitive cells are cultured in vitro, no circu-452 Cancer Cell 12, 445–456, November 2007 ª2007 Elsevier Ilating TNFa could be detected in the sera from HCC461
tumor-bearing mice using the same method (data not
shown). Consistently, admission of the TNFa neutralizing
antibody to HCC461 tumor-bearing mice also did not
block tumor shrinkage after Smac-mimetic treatment
(data not shown). It is possible that too little TNFa got
into the circulation and/or that most of it may act locally
at the tumor site. A more sensitive method able to detect
low levels of TNFa in sera and in the tumor will be needed
if this feature is going to be potentially developed into
a biomarker for single-agent sensitivity in human patients.
Another key aspect of the treatment was the observationnc.
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Autocrine TNFa Renders Smac Mimetic SensitivityFigure 6. Other Smac-Mimetic-Sensitive Cells Respond in a Similar Fashion as HCC461 Cells
Cell lines HCC44, MDA-MB-231, and SK MEL-5 were tested for rescue by siRNA transfection and neutralizing antibody pretreatments. siRNAs tar-
geting caspase-8, TNFR1, TNFa, and RIPK1 (Dharmacon siGENOME SMARTpool predesigned pools of four oligos), as well as neutralizing antibody
against TNFa (R&D Systems), were able to rescue these cell lines from Smac-mimetic-mediated apoptosis, while caspase-9 siRNA transfection




(D) H2009 cells were shown to respond to 100 nM compound 3 and 100 ng/ml TNFa. siRNA knockdown of caspase-8, TNFR1, andRIPK1were able to
rescue these cells from compound 3/TNFa cotreatment. siRNA transfection and cell viability assays were done as previously described. Each graph-
ical representation indicates the mean ± SD of at least three independent testing conditions.that animals treated with the Smac mimetic showed no
signs of associated cytotoxicity and were in general
good health.
While only 22% of non-small-cell lung cancer cell lines
examined responded to Smac-mimetic treatment alone,
some portion of the other 78% of cell lines that have no
response should respond to combined Smac mimetic/
TNFa (as shown for H2009) treatment, while another por-
tion will not respond at all (as in the case of HCC827 [data
not shown]). Why some cells respond and others do not is
a key issue facing cancer therapy in general. Unique differ-
ences in the nature of survival signaling and the mecha-
nism of evasion of apoptosis make this a remarkably
difficult task. It seems likely that as the ability of profiling
a unique tumor’s sensitivity to a variety of agents expands,
the utilization of various combination therapies should
specifically resolve this issue.
EXPERIMENTAL PROCEDURES
Reagents
Compound 3 and compound 4 were synthesized as previously
described (Li et al., 2004), and the biotinylated variant used for affinity
purifications was identical to that reported earlier, except the linkerCanconnecting the biotin motif to the Smac mimetic was five carbons
longer [synthesized using commercial (+)-biotinamidohexanoic acid
N-hydroxysuccinimide ester; see supporting information for Li et al.,
2004]. The compound was diluted to 100 uM stocks. Lung cancer
cell lines were obtained from the laboratory of Dr. John Minna (UT
Southwestern). Antibodies used: caspase-3 (Cell Signaling, 9662),
caspase-8 (Cell Signaling, 9746), TNFR1 (Abcam, ab19139), TNFa
(Cell Signaling, 3707), FADD (Cell Signaling, 2782), RIPK1 (BD Phar-
Mingen, 551041), TRADD (Cell Signaling, 3684), TNFa (R&D,
MAB210), FasL (Biolegend, 306408), and TRAIL (Biolegend, 308207).
Cell Culture
Cell lines HCC44, HCC461, HCC827, H2009, and MDA-MB-231 were
cultured in HyQ RPMI-1640 medium (Hyclone) supplemented with 5%
fetal bovine serum (FBS, Hyclone) and 100 units/ml penicillin/strepto-
mycin (GIBCO). SK MEL-5 cells were cultured in Minimum Essential
Medium (GIBCO) supplemented with 10% FBS, 100 units/ml penicil-
lin/streptomycin, and 2 mg/ml L-glutamine (GIBCO).
Cell Survival Assay
Cells were plated onto 96 well-assay plates (white with clear bottom
[3610], Corning Costar) at different cell densities, depending on cell
type, in 100 ml media per well. Cells were allowed to grow to near con-
fluence and treated with compound 3 or vehicle (H20) by adding 100 ml
media with compound 3, diluted to 23 the desired final concentration,
to each well. Cells were incubated overnight and assayed the following
day utilizing the Cell Titer-glo Luminescent Cell Viability Assaycer Cell 12, 445–456, November 2007 ª2007 Elsevier Inc. 453
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in live cells. As per manufacturer’s protocol, media was aspirated from
each well and 100 ml fresh media added. Cells were allowed to equili-
brate to room temperature when 100 ml of the Cell Titer-glo reagent
was added. Cells were placed on an orbital shaker for 2 min and
then were incubated for an additional 10 min. Luminescent measure-
ments were done on a Tecan SPECTRAFluor Plus 96-well plate reader.
For IC50 determination, half-maximal luminescent readings, relative to
the vehicle-treated cells, were considered to be representative of the
IC50 for each cell line tested. For assays measuring rescue effects,
all values were normalized to the mock-treated or mock-transfected
conditions to account for variability in the cytotoxicity of transfecting
siRNA into cells and for possible cytotoxic effects that knockdown of
the particular gene used might have. All values are represented graph-
ically as mean ± SD for three independent samples.
Western Blot Analysis of Caspase Activation and of siRNA
Knockdown Efficiency
HCC461 cells were plated onto 6-well cell culture dished (Corning
Costar) at differing cell densities, depending on the application, in
2 ml media. For caspase-activation determination, cells were plated
to near confluence and allowed to attach overnight. Cells were then
treated as indicated in Figure 2A. Cells were treated to a final concen-
tration of 100 nM compound 3 at each time point. For cells treated with
z vad fmk (Sigma), 10 mM z vad was added 1 hr prior to compound 3.
For siRNA knockdown efficiency, HCC461 cells were plated in 2ml an-
tibiotic-free media at a density of 83 104 cells per well and allowed to
attach overnight. siRNAs were then transfected as described below.
Cells were lysed in lysis buffer (20 mM Tris-HCl [pH 7.4], 150 mM
NaCl, 1% Triton X-100, 10%glycerol, 0.5mMDDT, and Complete pro-
tease inhibitor [Roche]) and were then incubated on ice for 20 min and
spun down at 10,000 RPM for 10 min. The soluble fraction was kept
and protein concentration determined by Bradford assay. Protein con-
centrations were normalized to 50 mg total and SDS-PAGE was done
followed by western blotting of target antibody.
Biotinylated Smac Mimetic Pull-Down
Cells were plated on 15 cmdishes and grown to confluence. Cells were
harvested and lysed as previously described. Biotinylated Smac
mimetic (100 nM) was preincubated with 20 ml (bead volume) strepta-
vidin dynabeads (Invitrogen) for 1 hr at 4C. Beads were then washed
two times in lysis buffer. Smac mimetic bound dynabeads were then
incubated with cell lysates overnight at 4C. The next day, beads
where washed four times with cell lysis buffer, and SDS-loading buffer
was added. Samples were run on SDS-PAGE and silver stained with
Bio-Rad silver stain plus kit. Bands for each lane were cut out for
mass spectrometry.
siRNA Transfection
siRNA transfections were done in both 6-well and 96-well dish formats.
For 6-well dishes, the day prior to transfection, cells were plated at
a density of 8 3 104 cells per well in antibiotic-free media. The next
day, Lipofectamine 2000 was used to transfect cells, as per manufac-
tures protocol. Briefly, 3 ml Lipofectamine 2000was combinedwith 120
pmol (6 ml of a 20 mM stock) siRNA in a volume of 500 ml Opti-mem
media (GIBCO) and incubated for 20 min; the complexes of Lipofect-
amine 2000 and siRNAs were then added directly to each well, and
the cells were incubated until nearly confluent, approximately 48–72 hr
later depending on growth conditions. For 96-well dishes, the day prior
to transfection, cells were plated at a density of 1.23 103 cells per well
in antibiotic-free media. Lipofectamine 2000 was used, as above, by
mixing 0.2 ml Lipofectamine 2000 and 8 pmol (0.4 ml of a 20 mM stock)
siRNA in a total volume of 50 ml. All siRNAs were purchased from Dhar-
macon. For caspase-8 and caspase-9, individual oligoswere designed
and tested (caspase-8-1 target sequence, 5-UGAAGAUAAUCAACGA
CUAUU-3; caspase-8-2 target sequence, 5-UGGAUUUGCUGAUUA
CCUAUU-3; caspase-8-3, obtained from Dharmacon [J-003466-14],
caspase-9-1 target sequence, 5-GAUGCCUGGUUGCUUUAAUUU;454 Cancer Cell 12, 445–456, November 2007 ª2007 Elsevier Icaspase-9-2, obtained from Dharmacon [J-003309-05]; caspase-9-
3, obtained from Dharmacon [J-003309-06]). For TNFR1 and TNFa,
individual oligos were purchased from Dharmacon (TNFR1: TNFR1-1,
J-005187-05; TNFR1-2, J-005197-06; TNFR1-3, J-005197-08) (TNFa:
TNFa-1, J-010546-09; TNFa-2, J-010546-10, TNFa-3, J-010546-12).
For all pooled siRNAs, Dharmacon’s siGENOME SMARTpool prede-
signed pools of four oligos were used and validated by western blot.
These included siRNAs for caspase-8, TNFR1, TNFa, FADD, TRADD,
and RIPK1.
Methylene Blue Viability Assay
Cells were plated onto 6-well dishes at low density and grown to 25%
confluence. Cells were then treated as indicated in Figure 2D. Five
days following treatment, cells were washed two times with cold
PBS, after which 2 ml methylene blue reagent was added (2% methy-
lene blue [w/v] in 50% ethanol) for 15 min. Cells were then washed with
water until all excess dye was removed. The plate was then photo-
graphed.
Elisa Analysis of Autocrine TNFa Secretion
Cells were plated onto 6-well dishes and allowed to grow to near
confluence (approximately 80%). Media was then aspirated and the
cells were washed two times with cold PBS. Fresh media (1 ml) was
added and 100 ml aliquots were removed at each time point (three
independent wells were tested at each time point). Samples were
kept at 20C until ready for use. Elisa analysis was performed using
a quantitative sandwich enzyme immunoassay from R&D Systems
(TNFa Quanti-glo Chemiluminescent Elisa, QTA00B), as per manufac-
turer’s instructions.
Caspase-8 Antibody Immunoprecipitation
Cells were grown on 15 cm plates, treated as indicated, and harvested
in 53 volume lysis buffer (as previously described). Cells were left on
ice for 20 min and centrifuged at 200003 g for 20 min. Twenty micro-
liters (bead volume) protein A agarose beads were coupled to 2 mg of
caspase-8 antibody (Santa Cruz, SC-6136) in 250 ml PBS (supple-
mented with 5 mg/ml BSA). After 2 hr incubation at room temperature,
the beads were washed two times in lysis buffer, whereupon 2 mg cell
lysates (2mg/ml) were added and incubated over night at 4C. The fol-
lowing day, beads were washed four times with lysis buffer and protein
eluted off the beads using low pH elution buffer (Pierce 21004). Elution
buffer was neutralized by adding 1:20 1 M Tris-HCl (pH 9.4). Samples
were then analyzed by SDS-PAGE followed by western blot.
In Vivo Matrigel Model of HCC461 and HCC15 Tumor Model
into Nude Mice
Harlan Athymic Nude-Foxnlnu 5- to 6-week-old mice were injected
subcutaneously with 1 3 107 HCC461 or HCC15 tumor cells in the
left flank. Seven days later, when tumors had reached 200–300 mm3
in size, mice were randomized into treatment groups of five mice per
group. Compound 3 was first dissolved in H2O at 20 mg/ml as the
stock solution and then diluted in PBS to 5 mg/kg based on the weight
of individual mice. The compound and the vehicle (saline) were admin-
istered intravenously in a total volume of 0.2 ml every other day for six
treatments total (q2d 3 6). Mice were weighed and tumors measured
using vernier calipers two times per week. Tumor volumes were calcu-
lated according to (length 3 width2)/2. All animal experiments were
performed in the vivarium of Joyant Pharmacology Department. The
animal protocol was approved by IACUC, which is valid until May 1,
2009. All animal experiments performed in Joyant conform to the rele-
vant regulatory standards. All values are represented graphically as the
mean ± SEM.
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